Modulus Discovery Signs Research Data Transfer Agreement with Astellas Pharma.
M2 PHARMA-May 31, 2019-Modulus Discovery Signs Research Data Transfer Agreement with Astellas Pharma
(C)2019 M2 COMMUNICATIONS
- Japanese early stage biopharmaceutical company Modulus Discovery, Inc has signed a research data transfer agreement on a specific drug target with Japanese drugmaker Astellas Pharma Inc. (TSX: 4503), the company said.
Under the terms of the agreement, Modulus plans to design, evaluate and optimise lead compounds for this target to rapidly identify a novel clinical candidate through leveraging its cutting-edge computational drug discovery platform.
Pursuant to the terms of the agreement, Modulus owns all rights to any small molecules that Modulus develops based on the provided data set.
Astellas will retain certain rights including a priority negotiation right for a certain period of time on clinical candidate compounds identified through Modulus' research based on the provided data.
This agreement demonstrates Modulus' unique approach to accessing and unlocking the value of existing preclinical opportunities in the industry which have been deprioritised or terminated due to technical reasons or changes in corporate strategy, and applying its proprietary computational technology platform and networked drug discovery model to efficiently deliver clinical candidates to market.
Through this effort, Modulus hopes to further its mission to "accelerate the discovery of new medicines for patients and their families" in need.
Modulus Discovery is a private Tokyo-based preclinical stage drug discovery company focused on rapid design and generation of small molecule clinical candidates for a range of high-value disease targets through the use of its cutting-edge computational drug discovery expertise and unique biology insights.
The international team at Modulus is comprised of drug design and disease biology experts with previous R and D experience at global pharmaceutical, biotechnology, and computational technology firms.
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Date:||May 31, 2019|
|Previous Article:||Vertex Selects Triple Combination Regimen of VX-445, Tezacaftor and Ivacaftor to Submit for Global Regulatory Approvals in Cystic Fibrosis.|
|Next Article:||Bioasis Appoints Saltarelli as Non-Executive Director.|